Almirall (XMAD:ALM) 5-Year Yield-on-Cost %: 1.51 (As of Jul. 09, 2026) — Near Median


XMAD:ALM Almirall SA XMAD:ALM
84 GF Score
Price €11.48
GF Value €12.35
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Almirall 5-Year Yield-on-Cost %?

Almirall XMAD:ALM -2.05% 84 5-Year Yield-on-Cost % is 1.51 as of Jul. 09, 2026, which is 7% below its 10-year median of 1.63. GuruFocus rates XMAD:ALM with a GF Score™ of 84/100 and a GF Value™ of €12.35 (Fairly Valued). The stock has 4 warning signs investors should review. Among 516 Drug Manufacturers companies, Almirall ranks worse than 61.05% on this metric.

Almirall's yield on cost for the quarter that ended in Mar. 2026 was 1.51.


The historical rank and industry rank for Almirall's 5-Year Yield-on-Cost % or its related term are showing as below:

XMAD:ALM' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.99   Med: 1.63   Max: 2.71
Current: 1.51


During the past 13 years, Almirall's highest Yield on Cost was 2.71. The lowest was 0.99. And the median was 1.63.


XMAD:ALM's 5-Year Yield-on-Cost % is ranked worse than
61.05% of 516 companies
in the Drug Manufacturers industry
Industry Median: 2.255 vs XMAD:ALM: 1.51

Almirall  (XMAD:ALM) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Almirall 5-Year Yield-on-Cost % Related Terms


XMAD:ALM vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Almirall's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Almirall 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Almirall's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Almirall's 5-Year Yield-on-Cost % falls into.


XMAD:ALM
84GF Score
Almirall SA XMAD:ALM
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Almirall 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Almirall is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 1.51 mean?
Almirall (XMAD:ALM) has a 5-Year Yield-on-Cost % of 1.51 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Almirall and its competitors. This is near median its historical median of 1.63. Over the past decade, Almirall's 5-Year Yield-on-Cost % has ranged from 0.99 to 2.71. According to the industry distribution chart, Almirall ranks #315 out of 516 companies in the Drug Manufacturers industry, placing it in the top 61%.
Is Almirall's 5-Year Yield-on-Cost % too high?
Almirall's current 5-Year Yield-on-Cost % of 1.51 is near median its 10-year median of 1.63. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 2.71. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.26. Almirall's value of 1.51 is 33% below this industry median. Based on the distribution chart, Almirall ranks #315 out of 516 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Almirall has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Almirall's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Almirall ranks #315 out of 516 companies for 5-Year Yield-on-Cost %. This places Almirall in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.26. Almirall's value of 1.51 is 33% below this benchmark. Historically, Almirall's own 5-Year Yield-on-Cost % has ranged from 0.99 to 2.71 over the past decade. While the company's 10-year median is 1.63 vs. the industry median of 2.26, Almirall has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.26, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Almirall's current 5-Year Yield-on-Cost % of 1.51 is 33% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Almirall and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Almirall's current 5-Year Yield-on-Cost % is 1.51, which is near median its own 10-year median of 1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Almirall stock overvalued right now?
Based on GuruFocus' analysis, Almirall (XMAD:ALM) is currently considered Fairly Valued. The stock's GF Value™ is €12.35, compared to a current price of €11.48 — trading 7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.51, which is near median its 10-year median of 1.63 and 33% below the Drug Manufacturers industry median of 2.26. Almirall's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Almirall (XMAD:ALM), the current 5-Year Yield-on-Cost % is 1.51 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Almirall (XMAD:ALM) Overvalued in 2026?

Based on GuruFocus' analysis, Almirall stock appears to be undervalued. The current stock price of €11.48 is trading 7% below its estimated GF Value™ of €12.35. GuruFocus considers Almirall to be Fairly Valued.

Key valuation signals for XMAD:ALM:

  • 5-Year Yield-on-Cost %: 1.51 (near median its 10-year median of 1.63)
  • GF Value™: €12.35 vs. price of €11.48 (7% below fair value)
  • GF Score™: 84/100 with 4 warning signs
  • Industry Position: 33% below the Drug Manufacturers median (#315 of 516)

No single metric tells the full story. See the XMAD:ALM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Almirall Business Description

Other Exchanges 0O9B:UKE2Z:Germany
Address Ronda General Mitre 151, Barcelona, ESP, 08022
Almirall SA is a skin-health focused pharmaceutical company based in Barcelona and the parent company of a group engaged in the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialities and products, as well as related raw materials. The Group applies science to provide medical solutions focused on skin health diseases and partners with healthcare professionals, and its activities also include cosmetics; chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food use; instruments and accessories for the chemical, pharmaceutical and clinical industry; and research on active chemical and pharmaceutical ingredients and products.
84GF Score

Get the complete analysis for XMAD:ALM

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.48
Price
€12.35
GF Value